Galera Therapeutics, Inc.
Corporate brand
UnclaimedGalera Therapeutics, Inc. is a Malvern, United States-based company developing small molecules targeting cancer vulnerabilities, including SOD mimetics and NOS inhibitors.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Galera Therapeutics, Inc. is a company in Malvern, United States. It develops small molecules targeting cancer vulnerabilities in tumor cells, in immune cells and in the tumor microenvironment, including superoxide dismutase (SOD) mimetics and nitric oxide synthase (NOS) inhibitors. Its SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress; avasopasem is in trials for hormone-resistant advanced breast cancer. Its NOS inhibitor tilarginine (L-NMMA) inhibits NO production and is undergoing trials in patients with metaplastic breast cancer and triple-negative breast cancer. The company states it is pioneering a new scientific approach with the goal of delivering new solutions for patients with breast cancer.
History
Galera Therapeutics, Inc. is a company in Malvern, United States. It develops small molecules targeting cancer vulnerabilities in tumor cells, in immune cells and in the tumor microenvironment, including superoxide dismutase (SOD) mimetics and nitric oxide synthase (NOS) inhibitors. Its SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress; avasopasem is in trials for hormone-resistant advanced breast cancer. Its NOS inhibitor tilarginine (L-NMMA) inhibits NO production and is undergoing trials in patients with metaplastic breast cancer and triple-negative breast cancer. The company states it is pioneering a new scientific approach with the goal of delivering new solutions for patients with breast cancer.
Products and positioning
Pioneering a new scientific approach with the goal of delivering new solutions for patients with breast cancer.
Avasopasem
SOD mimetic in trials for hormone-resistant advanced breast cancer.
Rucosopasem
SOD mimetic that mimics natural enzymes to convert superoxide into hydrogen peroxide.
Tilarginine (L-NMMA)
NOS inhibitor undergoing trials in patients with metaplastic breast cancer and triple-negative breast cancer.
Sources5 sources
- 1Pioneering Treatments for Patients with Breast Cancer - Galera Therapeutics, Inc.galeratx.com
- 2About Galera - Galera Therapeutics, Inc.galeratx.com
- 3About Galera - Galera Therapeutics, Inc.galeratx.com
- 4About Galera - Galera Therapeutics, Inc.galeratx.com
- 5Galera Therapeutics, Inc. (United States)wikidata.org
Cite this profile: Cite the canonical profile. /brand-wiki/galera-therapeutics-inc-united-states · Editorial policy · How profiles are compiled